▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Drugs world map

May 11, 2017 by Keith Speights

Actavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher

The specialty and generic drugmaker gets another boost from its 2016 purchase of Actavis Generics from Allergan.

Wrong - dictionary page

May 10, 2017 by Keith Speights

Investors Are Betting Big Against Marijuana Stock Insys Therapeutics -- Why They're Wrong

A lot of money has been put on the line thinking Insys Therapeutics stock could be in trouble. Here's why those betting against this marijuana stock could be the ones really in trouble.

Ben Franklin peaking through pills

May 10, 2017 by Keith Speights

Acquisitions Drive Mylan N.V. Revenue and Earnings Higher in Q1

The drugmaker enjoys strong gains internationally thanks to its Meda acquisition, but faces some headwinds in North America.

young couple worried looking at bill expense finance

May 10, 2017 by Keith Speights

6 States Where the Average Health Insurance Premium Tops $400 a Month

These states have the most expensive health insurance in the country, and premiums continue to soar.

Cancer cells

May 9, 2017 by Keith Speights

Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update

The clinical-stage biotech reports higher quarterly revenue thanks to its combination studies with Bristol-Myers Squibb.

Dollar signs in capsule

May 9, 2017 by Keith Speights

Valeant Pharmaceuticals Raises Full-Year Outlook After Posting a First-Quarter Profit

First-quarter sales declined as expected, but a one-time tax benefit helped the drugmaker return to profitability.

Surgeon touching screen with medical icons

May 9, 2017 by Keith Speights

What Is Digital Health?

If you're wondering what digital health is, here's what you need to know.

Financial report with blue overlay

May 8, 2017 by Keith Speights

Diplomat Pharmacy, Inc. Q1 Earnings Suffer From Hepatitis C Headwinds and Higher DIR Fees

The specialty pharmacy grew revenue in Q1 but continued to face challenges from a decline in hep-C sales and higher payer fees.

Pulse oximeter

May 8, 2017 by Keith Speights

Masimo Corporation Full-Year 2017 Outlook Improves After a Strong Q1 Performance

The non-invasive monitoring technologies leader reports higher revenue and earnings on solid shipments of its pulse oximetry products.

Marijuana buds on money

May 7, 2017 by Keith Speights

2 Compelling Reasons to Sell Marijuana Stocks – and 1 Reason Why You Shouldn’t

Is it time to sell marijuana stocks?

Marijuana buds with gavel

May 7, 2017 by Keith Speights

Jeff Sessions Won't Get a Penny to Go After States Legalizing Marijuana: Good News for Marijuana Stocks?

Will the new federal spending bill mean marijuana stocks will go even higher?

Man pulling piece out of block tower

May 7, 2017 by Keith Speights

Why Biogen Inc. Shareholders Have Something to Worry About

Biogen has a great thing going with Spinraza, but there are big questions for its multiple sclerosis franchise and pipeline prospects.

Businessman in front of 2 arrows

May 7, 2017 by Keith Speights

Better Buy: Amgen Inc. vs. Johnson & Johnson

How Amgen and Johnson & Johnson stack up against each other on growth prospects, valuation, and dividends.

Question sign in road

May 5, 2017 by Keith Speights

What to Expect From Valeant Pharmaceuticals' Q1 Results

Will Valeant show improvement in the first quarter? There are several factors that could make doing so difficult.

Cells

May 5, 2017 by Keith Speights

Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration

The clinical-stage biotech posts much higher top-line results in Q1 with an influx in cash from its big partner, Celgene.

Doctor with stethescope touching computer interface

May 5, 2017 by Keith Speights

10 Things Trumpcare Changes in Healthcare

How might Trumpcare impact your healthcare coverage? Here's what you need to know.

Out of business sticky note

May 16, 2017 by Keith Speights

What Percentage of Businesses Fail in Their First Year?

More businesses survive past their first year than you might expect. And that could be bad news for entrepreneurs.

Scientist at microscope

May 3, 2017 by Keith Speights

5 Things AbbVie Management Just Said That You'll Want to Know

Top AbbVie executives talk about protecting Humira, tax reform, and other key topics at the Deutsche Bank healthcare conference.

Reading document with magnifying glass

May 3, 2017 by Keith Speights

Gilead Sciences' 5-Point Plan to Turn Things Around

Gilead management's comments in the biotech's first-quarter conference call hint at a comeback strategy. But it might take a while.

Businessman silhouttte looking at cityscape

May 16, 2017 by Keith Speights

What You Can Learn From the Most Successful CEOs

Great career lessons from five top CEOs.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services